Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis

Stem Cell Research and Development- Market Trends, Investment Trends and Pipeline Analysis

Online PR News – 05-February-2010 – – GBI Research analysis suggests that stem cell therapies have immense market potential, driven by a strong pipeline that caters to high unmet needs. Increasing investment and a supportive regulatory environment in key geographies will help the stem cells industry to realize the potential.
Stem cell therapies high market potential is based on their unique ability to offer curative treatment in comparison to the symptomatic treatment offered by conventional treatments. From a commercial perspective, many diseases that arise as a result of irreversible damage of terminally differentiated cells, currently have large unmet needs that cannot be served based on conventional pharmaceutical and biotech research. Not serving these unmet needs results in lost growth opportunities for the pharmaceutical industry. Stem cell research has the potential to serve these unmet needs by providing alternatives to conventional pharmaceutical and biotech research which target the symptoms more than the cause.

For more information, please click or add the below link to your browser:

Stem cell therapies are expected to serve the unmet needs that are associated with the treatment of certain chronic diseases. In spite of advancements in medical technologies, there are very few treatment options available in the market to cure certain cardiovascular disorders, cancers, autoimmune and inflammatory disorders, spinal cord injury and others. Also, most of these therapies treat the symptoms without curing the disease. Stem cell therapies will fill this gap of unmet need through its novel therapeutic approach that has the ability to cure the diseases.

Strategic partnerships between Pharmaceutical companies and Stem cell research companies have given a boost to stem cell research and development. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug. Usually animal or tumor cells are being used and this leads to jury-rigged tests. Hence, all major pharmaceutical companies look forward to new technologies that increase the possibility to launch new therapies in the market place. At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies. Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next five years. Pharmaceutical companies are also keen to explore various methods where stem cells could be utilized in the drug discovery process that would accelerate the discovery of novel drug molecules.

For more information, please click or add the below link to your browser:

The total number of stem cell clinical trials has increased tremendously over the last few years. The number of Phase II clinical trials has witnessed more than a 40% jump between 2005 and 2008. With more than five ongoing Phase III trials, the market is keenly awaiting the launch of these therapies within the next five years. The Preclinical research and Phase I trials have also increased at a phenomenal rate. This increase demonstrates the emerging interests in stem cell research across the globe.

GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis”. It is an essential source of information and analysis on global stem cell research and development. The report identifies the key trends shaping and driving stem cell research and development. The report analyses investment decisions within the stem cell research market by providing information on pipelines, federal spending, investor perspectives, regulatory environment, competitive landscape and market potential. The study also provides insight on the prevalent competitive landscape and the emerging players expected to significantly shift the market positioning. Most importantly, the report provides valuable insight on the pipeline products within the global stem cell industry.

For more information, please click or add the below link to your browser:

Or visit our report store:

Contact Information
Rajesh Gunnam
Progressive House, Maidstone Road, Foots Cray, Sidcup
Kent London, DA14 5HZ